Opus Genetics | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 755 KEarnings Watch·Aug 6 at 06:06 AMIRD-1.70%
Opus Genetics releases Q2 2026 financials, along with corporate update. #businessnews #Q22026Unusual Whales·Aug 6 at 06:04 AMIRD-1.70%
Opus Genetics completes enrollment in Phase 3 trial of OPGx-LCA5 gene therapy for LCA5 retinal diseasePUBT·Aug 3 at 06:04 AMIRD-1.70%
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal DiseaseUnusual Whales·Aug 3 at 06:03 AMIRD-1.70%
Opus Genetics, Inc. $IRD Shares Sold by Perceptive Advisors LLCMarket Beat·Aug 2 at 05:16 AMIRD-1.70%
Top 3 Health Care Stocks That May Rocket Higher In Julybenzinga_article·Jul 20 at 05:03 AMLEGN+2.63%IRD-1.70%
Cantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)Tip Ranks·Jul 10 at 06:36 AMIRD-1.70%
Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target UnchangedTip Ranks·Jul 9 at 09:55 AMIRD-1.70%
Opus Genetics to release 3-month Cohort 1 topline data for OPGx-BEST1 trial in September 2026PUBT·Jul 9 at 06:01 AMIRD-1.70%
Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price TargetTip Ranks·Jul 6 at 12:15 PMIRD-1.70%
